New hope for tough leukemia: dual attack trial begins
NCT ID NCT07283640
Summary
This early-stage study aims to find a safe and effective dose of two drugs, revumenib and blinatumomab, given together for adults with a specific genetic type of acute lymphoblastic leukemia (ALL). It will enroll about 20 adults, including those newly diagnosed and those whose cancer has returned or resisted treatment. The main goals are to check for side effects and see if the combination can put the cancer into remission.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLINATUMOMAB are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer
Houston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.